MOESM2 of 
                     GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Adele Busico (3422972); Alessia Mennitto (3422978); Annunziata Gloghini (32268); Claudia Maggi (545430); Dario Baratti (3422990); Elena Tamborini (3422993); Federica Perrone (545433); Filippo de Braud (545440); Filippo Pietrantonio (545429); Giulio Settanni (3422996); Ilaria Bossi (545437); Luigi Mariani (3399464); Marcello Deraco (3422999); Maria Di Bartolomeo (545431); Marta Caporale (3422984); Massimo Milione (545439); Monica Niger (3422975); Pietro Bagnoli (3422987); Rosa Berenato (3423002); Shigeki Kusamura (3422981)

MOESM2 of GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Abstract

Additional file 2: Figure S1. Comparison of Kaplan-Meier curves for progression-free survival according to GNAS mutational status in the retrospective cohort (FOLFOX-4)

Similar works

Full text

Available Versions

FigShare

oai:figshare.com:article/43337...

Last time updated on 12/02/2018